TAMPA, FL, February 21, 2023 – EV Biologics Corp (OTC PINK:YECO), announced that it has successfully generated several mesenchymal stem/stromal cell (MSC) lines for secretome production and further cell line development. The cell banks were isolated from rigorously screened human donor tissue using xeno-free, serum-free culture media for isolation and expansion, after obtaining informed consent (from donors) for research and development. Analysis of the cell lines confirmed their identity as MSCs according to established criteria. [Read more…]
Heartseed and Novo Nordisk Dose First Patient with HS-001, an iPSC-Derived Cell Therapy to Treat Heart Failure
HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs).
Clinical phase 1/2 study (LAPiS Study) will enroll 10 patients with advanced heart failure caused by ischaemic heart disease.
Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has given approval for the study to continue. [Read more…]
The European Innovation Council (EIC) awards the AcouSort project AcouSome SEK 26 million to develop groundbreaking technology for exosome-based diagnostics
August 13, 2022, Lund, Sweden – Exosomes are nanoparticles that enable human cells to communicate vital information with each other. They have potential to open a completely new field within diagnostics, as they can give us ‘status reports’ on organs such as the brain and heart, as well as give us vital information on tumor diseases, infectious diseases, pregnancy and stem cell conditions. EIC has announced that it granted AcouSort and its project partners SEK 26 million to develop an acoustofluidic thin-film actuated chip for exosome separation from blood. Of the SEK 26 million, SEK 12.2 million go directly to AcouSort, and the remainder of the funding is distributed to AcouSort’s partners Lund University, DTU, and Day One. The project will run for 36 months and is fully funded by the EU. [Read more…]
New Super-Potent Topical Exosome Cosmetics Product, Distributed in UAE by Great Look Medical Supplies, to be Unveiled at Dubai Derma 2023 Conference March 1st- 3rd
ROCHESTER, NY and DUBAI, UAE, Feb. 17, 2023 – On March 1, Resiliélle Cosmetics, LLC and Regenerelle Biotherapeutics will unveil their new Resiliélle brand topical exosome cosmetics product manufactured by Regenerelle and exclusively distributed worldwide by Resiliélle. Resiliélle’s product will set a new standard for skin rejuvenation and lustrous hair. For optimal results, aesthetics professionals may use Resiliélle topically after microneedling or laser treatments. Resiliélle believes that the use of our topical exosome cosmetics will allow MedSpa, Dermatology and Plastic Surgery patients to use Resiliélle topical exosome cosmetics that have been developed to help patients to Leap Back In Time™ — At Any Age.™ [Read more…]
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors
FUKUOKA, Japan, and BORDEAUX, France / February 15th, 2023 – GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells. [Read more…]
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 118
- Next Page »